Magnesium depletion can contribute to obesity through disrupted metabolic signaling, insulin sensitivity, and gut microbiota shifts that favor fat storage. Low magnesium impairs energy homeostasis and promotes low-grade inflammation, potentially worsening weight gain in susceptible individuals, especially those with poor diets. Mechanistic and observational links, though not yet confirmed by large RCTs, support monitoring body composition to address this reversible concern. This medication is commonly used for Stomach Acid.
Al Shammaa A, Al-Thani A, Al-Kaabi M, Al-Saeed K, Alanazi M, Shi Z. Serum Magnesium is Inversely Associated with Body Composition and Metabolic Syndrome. Diabetes Metab Syndr Obes. 2023 Jan 12;16:95-104. Lu L, Chen C, Yang K, Zhu J, Xun P, Shikany JM, He K. Magnesium intake is inversely associated with risk of obesity in a 30-year prospective follow-up study among American young adults. Eur J Nutr. 2020 Dec;59(8):3745-3753. Oliveira AR, Cruz KJ, Severo JS, Morais JB, Freitas TE, Araújo RS, Marreiro DD. Hypomagnesemia and its relation with chronic low-grade inflammation in obesity. Rev Assoc Med Bras (1992). 2017 Feb;63(2):156-163. Cazzola R, Della Porta M, Piuri G, Maier JA. Magnesium: A Defense Line to Mitigate Inflammation and Oxidative Stress in Adipose Tissue. Antioxidants (Basel). 2024 Jul 24;13(8):893.
Some side effects may be linked to nutrient depletion caused by this medication.
Studies find that proton pump inhibitors (PPIs) may increase your risk of magnesium deficiency. A large study involving over 100,000 participants found a significant association between PPI use and lower magnesium levels (hypomagnesemia). PPIs work by reducing stomach acid production, which can also play a role in magnesium absorption. Individuals taking PPIs, particularly long-term use, should consider magnesium supplementation to help protect against deficiency.
Long-term use of PPIs might raise the risk of calcium deficiency and weaken bones. A potential mechanism for this is chronic hypergastrinemia, a condition where the stomach produces excess gastrin due to PPI use. This can lead to parathyroid hyperplasia, where the parathyroid glands overproduce a hormone that pulls calcium from bones. Additionally, PPIs significantly reduce stomach acid production, which can hinder calcium absorption from food in the intestines. Individuals taking PPIs, especially individuals at higher risk of bone issues or those on long-term PPI therapy, should consider calcium supplementation to help protect against deficiency.
There is evidence that proton pump inhibitors (PPIs) might decrease vitamin C levels in the body. A study showed that even a short course of omeprazole, a common PPI, reduced vitamin C levels in healthy volunteers, regardless of their dietary intake. This suggests that PPIs may reduce the bioavailability of vitamin C, meaning the body has a harder time absorbing and using it. Vitamin C plays a crucial role in immune function and antioxidant defenses and therefore individuals using PPI therapy should consider supplementation with vitamin C to protect against a deficiency.